The company said fourth-quarter net revenues for Q4 2023 fell to $2,288 million from a year earlier, down 1.9% from 2022, and full-year net revenues fell 6.4% to $9,252 million. Excluding COVID-19 testing, base business revenues rose 7.1% to $9,029 million for the full year.

1. 01

   The company said fourth-quarter net revenues for Q4 2023 fell to $2,288 million from a year earlier, down 1.9% from 2022, and full-year net revenues fell 6.4% to $9,252 million. Excluding COVID-19 testing, base business revenues rose 7.1% to $9,029 million for the full year.

2. 02

   Quest Diagnostics said full-year 2023 reported diluted EPS fell 6.0% from 2022 to $7.49, and adjusted diluted EPS fell 12.5% to $8.71. Reported diluted EPS for Q4 was $1.70, and adjusted diluted EPS was $2.15.

3. 03

   The company said cash provided by operations for full-year 2023 fell 25.9% from 2022 to $1,272 million. It repurchased 2.0 million shares for $276 million over the same period, and $1.0 billion remained available under its share repurchase authorization as of December 31, 2023.

4. 04

   The company said it raised its quarterly dividend 5.6% from $0.71 to $0.75 per share. It also gave full-year 2024 guidance of net revenues of $9.35 billion to $9.45 billion and adjusted diluted EPS of $8.60 to $8.90.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.